Nektar Therapeutics

NasdaqCM:NKTR 주식 보고서

시가총액: US$215.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Nektar Therapeutics 대차 대조표 상태

재무 상태 기준 확인 5/6

Nektar Therapeutics 의 총 주주 지분은 $126.7M 이고 총 부채는 $117.9M, 이는 부채 대 자기자본 비율을 93% 로 가져옵니다. 총자산과 총부채는 각각 $396.0M 및 $269.3M 입니다.

주요 정보

134.9%

부채 비율

US$107.51m

부채

이자 보상 비율n/a
현금US$271.24m
주식US$79.69m
총 부채US$263.65m
총 자산US$343.33m

최근 재무 상태 업데이트

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nov 06
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Apr 24
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Jan 24
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Recent updates

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

Jun 19
Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Feb 15
There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Dec 31
Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nov 06
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Apr 24
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Jan 24
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Aug 19
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Nektar: Time To Abandon Ship

Jul 17

Nektar promotes internal executive to CFO role

Jul 01

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

May 11
We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline

Apr 04

Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts

Mar 09
Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts

Nektar Therapeutics: Beaten Down By 2020

Jan 26

We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth

Jan 13
We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth

Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Trimmed Their Revenue Forecasts By 11%

Dec 09
Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Trimmed Their Revenue Forecasts By 11%

재무 상태 분석

단기부채: NKTR 의 단기 자산 ( $319.8M )이 단기 부채( $52.4M ).

장기 부채: NKTR 의 단기 자산( $319.8M )이 장기 부채( $216.9M ).


부채 대 자본 내역 및 분석

부채 수준: NKTR 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: NKTR 의 부채 대 자기자본 비율은 지난 5년간 20.9% 에서 134.9% 로 증가했습니다.


대차 대조표


현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: NKTR 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: NKTR 31.5 1.8 31.5 % 매년.


건강한 기업 발견하기